Medicinal compositions containing aspirin

ABSTRACT

A combination of 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, which possess excellent inhibitory activity against platelet aggregation and thrombogenesis, and is useful for preventing or treating diseases caused by thrombus or embolus.

[0001] This is a Continuation Application of International ApplicationNo. PCT/JP01/11201 filed Dec. 20, 2001 which is incorporated herein byreference in its entirety.

BACKGROUND OF THE INVENTION

[0002] This invention relates to pharmaceutical compositions containing2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridineor a pharmaceutically acceptable salt thereof, and aspirin, as activeingredients [particularly pharmaceutical compositions for prevention ortreatment (particularly for treatment) of diseases caused by thrombus orembolus]; to the use of2-acetoxy-5-α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridineor a pharmaceutically acceptable salt thereof and aspirin for themanufacture of pharmaceutical compositions for prevention or treatment(particularly for treatment) of diseases caused by thrombus or embolus;and to methods for the prevention or treatment (particularly to methodsfor the treatment) of diseases caused by thrombus or embolus byadministration of an effective amount of2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridineor a pharmaceutically acceptable salt thereof and aspirin towarm-blooded animals (particularly humans).

[0003]2-Acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridinehas been described in the Japanese Patent Application Publication No.Hei 6-41139, and possesses potent inhibitory activity against plateletaggregation. Furthermore, aspirin is well known to have an inhibitingactivity against platelet aggregation, although the activity is low.However, pharmaceutical compositions containing both compounds have notbeen known.

BRIEF DESCRIPTION OF THE INVENTION

[0004] The present inventors have studied therapeutic agents with lowtoxicity that exert inhibitory activity against platelet aggregation andhave found that the problems described above are solved by usingpharmaceutical compositions comprising2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridineor a pharmaceutically acceptable salt thereof and aspirin.

DETAILED DESCRIPTION OF THE INVENTION

[0005] The present invention provides pharmaceutical compositionscontaining2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridineor a pharmaceutically acceptable salt thereof and aspirin as activeingredients [particularly pharmaceutical compositions for prevention ortreatment (particularly for treatment) of diseases caused by thrombus orembolus]; the use of2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridineor a pharmaceutically acceptable salt thereof, and aspirin, for themanufacture of pharmaceutical compositions [particularly pharmaceuticalcompositions for prevention or treatment (particularly for treatment) ofdiseases caused by thrombus or embolus]; and methods for the preventionor treatment (particularly methods for treatment) of diseases caused bythrombus or embolus by administration of an effective amount of2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridineor a pharmaceutically acceptable salt thereof, and aspirin, towarm-blooded animals (particularly humans), simultaneously orsequentially.

[0006]2-Acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine,and pharmaceutically acceptable salts thereof, which is one of theactive ingredients of the present invention, is a known compound. Forinstance, the compound has already been described in Japanese PatentApplication Publication No. Hei 6-41139 and Japanese Patent ApplicationPublication No. 2002-145882 (priority: Japanese Patent Application No.2000-205539, and Japanese Patent Application No. 2000-266780). Thechemical structure is described below.

[0007] The pharmaceutically acceptable salts of2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridinemay be, for example, hydrohalogenic acid salts such as hydrofluoride,hydrochloride, hydrobromide or hydroiodide; nitrate; perchlorate;sulfate; phosphate; C₁-C₄ alkanesulfonates optionally substituted byhalogens such as methanesulfonate, trifluoromethanesulfonate,ethanesulfonate; C₆-C₁₀ arylsulfonates optionally substituted by C₁-C₄alkyl groups such as benzenesulfonate or p-toluenesulfonate; C₁-C₆aliphatic acid salts such as acetate, malate, fumarate, succinate,citrate, tartarate, oxalate or maleate; amino acid salts such as glycinesalt, lysine salt, arginine salt, ornitine salt, glutamic acid salt oraspartic acid salt; and the preferred compounds are hydrohalogenates orC₁-C₆ aliphatic acid salts; and more preferred compounds are thehydrochloride or the maleate.

[0008] When one of the active ingredients of the present invention,2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridineor a pharmaceutically acceptable salt thereof, is allowed to stand sothat it is open to the atmosphere, it may become hydrated by absorptionof water or adsorption of water. Such hydrated compounds are included inthe present invention.

[0009] Further, one of the active ingredients of the present invention,2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridineor a pharmaceutically acceptable salt thereof, may absorb some kinds oforganic solvents and may form solvates in some cases, and these solvatesare also included in the present invention.

[0010] Furthermore, since2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridinehas an asymmetric carbon atom, optical isomers exist based on theasymmetric carbon atom. These optical isomers are also included in thepresent invention.

[0011] The other active ingredient, aspirin, is a well-known compound,as an analgesic antipyretic.

[0012] The pharmaceutical compositions of the present invention(particularly pharmaceutical compositions for the prevention ortreatment of diseases caused by thrombus or embolus) which contain2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridineor a pharmaceutically acceptable salt thereof, and aspirin, as activeingredients, possess excellent inhibitory activity against plateletaggregation and thrombogenesis with short onset latency and lowtoxicity. Thus the pharmaceutical compositions of the present inventionare useful as preventative or therapeutic agents (particularly astherapeutic agents) against diseases caused by thrombus or embolus, forexample, diseases induced by platelet aggregation, including stable orunstable angina pectoris and so forth; cardiovascular or cerebrovasculardisorders, e.g., thromboembolism, associated with atherosclerosis ordiabetes mellitus, such as unstable angina pectoris, cerebral ischemicinsult or restenosis due to angioplasty, endarterectomy or stenttherapy; or thromboembolism caused by thromboembolization such asrecurrent embolism after degradation of the original thrombus, embolism,ischemia-induced dementia, peripheral arteriopathy, thromboembolizationassociated with hemodialysis or atrial fibrillation, orthromboembolization in the vascular prosthesis, or in the bypass betweenthe aorta and the coronary artery. Furthermore, the therapeutic agent ofthe present invention is administered to warm-blooded animals(particularly humans).

[0013] According to the present invention, the use in combination of2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridineor a pharmaceutically acceptable salt thereof, and aspirin, results inmore potent effectiveness than the use of each component alone.Furthermore, plasma levels of these agents do not have to be maintainedat a certain level and higher during the same period, in order toproduce their effects. It is believed that these 2 agents reach thereceptors, at which they act in vivo, and turn on switches at thereceptors to induce the effects. Even though the plasma level of onecomponent of the pharmaceutical composition is too low to induce theeffects with increasing time after the agent was administered, theswitches at the receptors have already been turned on. Thus thepreventative or therapeutic efficacy of the agent is expected byinhibiting thrombogenesis or embolization.

[0014] Therefore, when the other component of the pharmaceuticalcomposition is administered later, the therapeutic effect of thecompound administered later is expected to add to the therapeuticeffects of the previously administered component. However, it isconvenient clinically that both components are administered at the sametime. Thus2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridineor a pharmaceutically acceptable salt thereof and aspirin aresimultaneously administered as a combination drug. In the case that bothagents cannot be mixed technically, each component can be administeredseparately. Moreover, as described previously, since each componentproduces significant effects as a single form, each component can besequentially administered at appropriate intervals. The maximumintervals between administration of each of the two components that canbe accepted to elicit significant effects could be confirmed by clinicaltrials or animal studies.

[0015] The route for administration of2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridineor a pharmaceutically acceptable salt thereof, and aspirin, which isemployed in the present invention, is generally the oral route. However,other routes, for example, intravenous administration, can be used.Thus, the 2 components can be prepared respectively as separateformulations, or can be mixed physically to form a single formulationfor administration. The single formulations of the mixed components are,for example, powders, granules, tablets, capsules and so forth, and canbe prepared by regular formulation techniques, as described below.

[0016] These formulations are prepared by conventional methods by usingexcipients (organic excipients, for example, sugar derivatives such aslactose, sucrose, glucose, mannitol or sorbitol; starch derivatives suchas corn starch, potato starch, α-starch or dextrin; cellulosederivatives such as crystalline cellulose; gum arabic; dextran; orpullulan; and inorganic excipients, for example, silicate derivativessuch as light silicic acid anhydride, synthetic aluminum silicate,calcium silicate or magnesium aluminate metasilicate; phosphatederivatives such as calcium hydrogenphosphate; carbonates such ascalcium carbonate; or sulfates such as calcium sulfate), lubricants (forexample, stearic acid; metal stearate derivatives such as calciumstearate or magnesium stearate; talc; waxes such as beeswax orspermaceti; boric acid; adipic acid; sulfate derivatives such as sodiumsulfate; glycol; fumaric acid; sodium benzoate; DL-leucine; laurylsulfate derivatives such as sodium lauryl sulfate or magnesium laurylsulfate; silicic acid derivatives such as silicic acid anhydride orsilicic acid hydrate; and starch derivatives described above), binders(for example, hydroxypropyl cellulose, hydroxypropylmethylcellulose,poly(vinylpyrrolidone), polyethylene glycol and similar compoundsdescribed in the above excipients), disintegrators (for example,cellulose derivatives such as low substituted hydroxypropylcellulose,carboxymethylcellulose, calcium carboxymethylcellulose, internallycross-linked sodium carboxymethylcellulose; chemically modifiedstarch/cellulose derivatives such as carboxymethylstarch, sodiumcarboxymethylstarch; cross-linked polyvinylpyrrolidone; or starchderivatives described above), emulsifiers (for example, colloidal clayssuch as bentonite or veegum; metal hydroxides such as magnesiumhydroxide or aluminum hydroxide; anionic surfactants such as sodiumlauryl sulfate or calcium stearate; cationic surfactants such asbenzalkonium chloride; or nonionic surfactants such as polyoxyethylenealkyl ether, polyoxyethylenesorbitan ester of fatty acids or sucroseester of fatty acids), stabilizers (for example, parahydroxybenzoatessuch as methylparaben or propylparaben; alcohols such as chlorobutanol,benzyl alcohol or phenylethyl alcohol; benzalkonium chlorides; phenolderivatives such as phenol or cresol; thimerosal; dehydroacetic acid; orsorbic acid), corrigents (for example, sweetening, souring and flavoringagents all of which are conventionally used), and diluents.

[0017] The dose and the dose ratio of2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridineor pharmaceutically acceptable salt thereof, and aspirin, can be widelyaltered based on several factors such as activity of each compound, andthe symptoms, age and body weight of the patients.

[0018] Generally, the lower limit of the oral dose (mg drug dose/time)is 0.1 mg (preferably, 1 mg) per time, while the upper limit is 1,000 mg(preferably, 500 mg) per time. The lower and upper limits of intravenousinjection are 0.01 mg (preferably, 0.1 mg) and 500 mg (preferably, 250mg), respectively. They are administered to the adult from 1 to 7 timesa day based on the symptoms of the patient, simultaneously orsequentially.

[0019] Generally, the dose ratio of2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridineor pharmaceutically acceptable salt thereof, and aspirin, is from 1:500to 500:1 as their weight ratio.

EXAMPLES

[0020] The present invention is described in detail with examples andformulations in the following. However, the claim of the presentinvention is not restricted to the following description.

Example 1

[0021] Inhibitory Activity Against Thrombogenesis

[0022] As the test animals, male Sprague Dawley rats of 7 weeks old werepurchased from SLC Japan and 6 rats per group were used.

[0023]2-Acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridinewas synthesized according to the method described in the Specificationof Japanese Patent Application Publication No. Hei 6-41139 and was used,while aspirin was purchased from Sigma Chemical Co. and was used. Bothcompounds were suspended in 5% (w/v) gum arabic solution, and werediluted so as to be 1 ml/kg of administration volume and were orallyadministered.

[0024] The inhibitory activities of the compounds against thrombogenesisor thrombus formation were evaluated in the modified arterio-venousshunt thrombosis model in rats, which was described by Umetsu et al.[Thromb. Haemost., 39, 74-83 (1978)].

[0025] The shunt tube was prepared as follows; i.e., both sides of amedical silicon tube of 12 cm length [inner diameter: 1.5 mm, outerdiameter: 2.5 mm, purchased from KANEKA Medix Co., Ltd] were connectedeach to a polyethylene tube of 7 cm length [inner diameter: 0.5 mm,outer diameter: 1.0 mm, purchased from Natsume Seisakusho Co., Ltd.]covered with silicon via a medical silicon tube of 0.7 cm length [innerdiameter: 1.0 mm, outer diameter: 1.5 mm, KANEKA Medix Co., Ltd] asconnector. A surgical suture of 10 cm length was placed in the silicontube of 12 cm length.

[0026] The animal was anesthetized with an intraperitoneal injection of40 mg/kg of pentobarbital sodium (purchased from Abbott LaboratoriesInc.), and the jugular of one side and the carotid of the other sidewere exposed. The arteriovenous shunt was made by cannulation of a shunttube filled with heparin solution [30 units/kg, purchased from FusoPharmaceutical Co., Ltd] into the carotid and the jugular which had beenpreviously exposed.

[0027] The test compounds were orally administered and the blood wasstarted to circulate into the shunt area two hours after theadministration. Thirty minutes after the circulation was started, theshunt tube was removed, and the thrombus adsorbed on the surgical suturewas weighed. The results are shown in Table 1. The results in the tableare expressed as the average weight±SE (n=6). TABLE 1 Compounds CompoundA Aspirin Thrombus Weight Inhibition Rate (mg/kg) (mg/kg) (mg) (%) 0 052.3 ± 1.2 — 0 10 46.6 ± 2.8 12.3 ± 4.4 0.3 0 43.5 ± 2.1 17.0 ± 4.1 0.60 37.5 ± 2.1 28.3 ± 4.0 0.3 10 30.5 ± 3.5 41.8 ± 6.6 0.6 10 23.2 ± 3.855.7 ± 7.2

[0028] (Formulation 1) Tablets Compound A 10.0 mg Aspirin 12.5 mgLactose 175.5 mg  Corn starch 50.0 mg Magnesium stearate  2.0 mg Total 250 mg

[0029] The powders in the formula described in the above table aremixed, compressed with a tableting machine and formulated as a tabletcontaining 250 mg in total. The tablet can be coated with film or sugar,when necessary.

What is claimed is:
 1. A pharmaceutical composition comprising2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridineor a pharmaceutically acceptable salt thereof, and aspirin, in a ratioby weight of 1:500 to 500:1.
 2. The pharmaceutical composition of claim1 further comprising a pharmaceutically acceptable excipient.
 3. Thepharmaceutical composition of claim 1 wherein the2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridineis in the form of a pharmaceutically acceptable salt.
 4. Thepharmaceutical composition according to claim 3, wherein thepharmaceutically acceptable salt is the hydrochloride.
 5. Thepharmaceutical composition according to claim 3, wherein thepharmaceutically acceptable salt is the maleate.
 6. A method for theprevention of diseases caused by thrombus or embolus, comprisingadministering a pharmaceutical composition comprising2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridineor a pharmaceutically acceptable salt thereof, and aspirin, as activeingredients, in their pharmacologically effective amounts, to awarm-blooded animal.
 7. A method according to claim 6, in which thepharmaceutically acceptable salt is the hydrochloride or maleate.
 8. Amethod according to claim 6 or claim 7, in which the warm-blooded animalis a human.
 9. A method for the treatment of diseases caused by thrombusor embolus, comprising administering a pharmaceutical compositioncomprising2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridineor a pharmaceutically acceptable salt thereof, and aspirin, as activeingredients, in their pharmacologically effective amounts, to awarm-blooded animal.
 10. A method according to claim 9, in which thepharmaceutically acceptable salt is the hydrochloride or maleate.
 11. Amethod according to claim 9 or claim 10, in which the warm-bloodedanimal is a human.
 12. A method for the treatment of a patientundergoing stenting, angioplasty, and/or to prevent restenosiscomprising administering a pharmaceutical composition comprising2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridineor a pharmaceutically acceptable salt thereof, and aspirin, as activeingredients, in their pharmacologically effective amounts, to awarm-blooded animal.
 13. A method according to claim 12, in which thepharmaceutically acceptable salt is the hydrochloride or maleate.
 14. Amethod according to claim 12 or claim 13, in which the warm-bloodedanimal is a human.